share_log

Xebra Brands Ltd Executes Manufacturing Agreement With Restorative Botanicals

Xebra Brands Ltd Executes Manufacturing Agreement With Restorative Botanicals

Xebra Brands Ltd 與 Restorative Botanicals 簽署生產協議
Accesswire ·  03/27 00:45

VANCOUVER, BC / ACCESSWIRE / March 26, 2024 / Xebra Brands Ltd. ("Xebra" or the "Company") (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0), a cannabis company, is excited to announce the signing of a manufacturing agreement on March 22, 2024 with Restorative Botanicals, a leading provider of premium CBD products. This collaboration marks a significant milestone for Xebra as it enhances its product portfolio with it's first Mexican product launch of premium CBD tinctures.

不列顛哥倫比亞省溫哥華/ACCESSWIRE /2024年3月26日/大麻公司Xebra Brands Ltd.(“Xebra” 或 “公司”)(CSE: XBRA)(OTCQB: XBRAF)(FSE: 9YC0)很高興地宣佈於2024年3月22日與領先的CBD產品供應商Restorative Botanicals簽署生產協議。此次合作對於 Xebra 來說是一個重要的里程碑,因爲它在墨西哥首次推出優質 CBD 酊劑產品,從而增強了其產品組合。

Under the terms of the agreement, Restorative Botanicals will manufacture a bespoke CBD tincture exclusively for the Elements CBD brand, leveraging their expertise in crafting high-quality, cannabinoid-infused products. The CBD tinctures, tailored to meet Xebra's specifications, will offer consumers a premium wellness solution aimed at delivering on consumer needs.

根據協議條款,Restorative Botanicals將利用他們在製作注入大麻素的高質量產品方面的專業知識,專門爲Elements CBD品牌生產定製的CBD酊劑。爲滿足Xebra規格而量身定製的CBD酊劑將爲消費者提供旨在滿足消費者需求的優質健康解決方案。

The CBD products will be manufactured in the US, allowing Xebra to import finished products prior to receiving all federally approved confirmations from the COFEPRIS for domestically produced products. Xebra's long-term goal remains to manufacture locally in Mexico, but as consumers and retailers eagerly await domestically produced products, Xebra unlocks another commercial route through their import authorizations to satisfy these consumer needs. Xebra will introduce these Element branded products to prime the retail and commercial pathways in Mexico and lay the foundation for greater expansion and lower cost of production once domestic products are manufactured.

CBD產品將在美國製造,允許Xebra在收到COFEPRIS的所有聯邦批准的國產產品確認書之前進口成品。Xebra 的長期目標仍然是在墨西哥本地製造,但隨着消費者和零售商熱切地等待國產產品,Xebra 通過其進口許可開闢了另一條商業途徑,以滿足這些消費者的需求。Xebra 將推出這些 Element 品牌產品,爲墨西哥的零售和商業鋪平道路,併爲國內產品製造完成後進一步擴張和降低生產成本奠定基礎。

Restorative Botanicals is renowned for its commitment to quality and innovation in the CBD industry. With a focus on natural ingredients and sustainable practices, Restorative Botanicals has earned a reputation for delivering premium CBD products that prioritise consumer well-being.

修復性植物藥因其對CBD行業質量和創新的承諾而聞名。Restorative Botanicals專注於天然成分和可持續實踐,因提供優先考慮消費者福祉的優質CBD產品而贏得了聲譽。

The bespoke CBD tincture crafted by Restorative Botanicals for Xebra will feature:

Restorative Botanicals 爲 Xebra 精心製作的定製 CBD 酊劑將具有:

  • High-quality, broad-spectrum CBD extract sourced from organic hemp
  • Meticulously selected botanical ingredients for enhanced efficacy and flavor
  • Rigorous testing and quality assurance measures to ensure potency and purity
  • 源自有機大麻的高品質、廣譜 CBD 提取物
  • 精心挑選的植物成分可增強功效和風味
  • 嚴格的測試和質量保證措施,確保效力和純度

Rodrigo Gallardo, Interim CEO of Xebra Brands Ltd, commented, "We are excited to partner with Restorative Botanicals to commercialize our unique product offerings ahead of domestic production. This collaboration ignites a commercial pathway to revenue by allowing our team to unlock the Mexican CBD market and start forging partnerships with retailers and commercial outlets."

Xebra Brands Ltd臨時首席執行官羅德里戈·加拉多評論說:“我們很高興與Restorative Botanicals合作,在國內生產之前將我們獨特的產品商業化。這種合作使我們的團隊能夠開啓墨西哥CBD市場,並開始與零售商和商業網點建立合作伙伴關係,從而點燃了一條商業創收之路。”

For more information, please contact:

欲了解更多信息,請聯繫:

Rodrigo Gallardo Interim CEO
+1 (833) XEBRA 88
ir@xebrabrands.com

羅德里戈·加拉多臨時首席執行官
+1 (833) XEBRA 88
ir@xebrabrands.com

Cautionary Note Regarding Forward-Looking Information

關於前瞻性信息的警示說明

Certain information contained in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements, these include, without limitation, statements regarding Xebra Brands Ltd.'s expectations in respect of its ability to successfully execute its business plan or business model, the ability to obtain necessary approvals in connection with the Debt Settlement; its ability to enter into and execute partnerships or joint venture opportunities on acceptable terms; its ability to provide economic, environmental, social, or any benefits of any type in the communities it operates in or may operate it in the future; its ability to be a first mover in a country, or to obtain or retain government licenses, permits or authorizations in general, or specifically in Mexico, Canada, or elsewhere, including cannabis authorizations from the Mexican Health Regulatory Agency (COFEPRIS); its ability to satisfy the conditions of authorizations granted by COFEPRIS; its ability to successfully apply for, obtain and retain trademarks and other intellectual property in any jurisdiction; its ability to be cost competitive; its ability to commercialize, cultivate, grow, or process hemp or cannabis in Mexico, Canada, or elsewhere and related plans and timing; its ability to manufacture, commercialize or sell its CBD products,, wellness products, or other products in Mexico, Canada, or elsewhere, and its related plans and claims, including market interest and availability; its ability to create wellness products that have a therapeutic effect or benefit; plans for future growth and the direction of the business; plans to increase product volumes, the capacity of existing facilities, supplies from third party growers and contractors; expected growth of the cannabis industry generally; management's expectations, beliefs and assumptions in general, including manufacturing costs, production activity and market potential in Mexico or any jurisdiction; events or developments that Xebra expects to take place in the future; general economic conditions; and other risk factors described in the MD&A of the Company for the period ended November 30, 2023. All statements, other than statements of historical facts, are forward-looking information and statements. The words "aim", "believe", "expect", "anticipate", "contemplate", "target", "intends", "continue", "plans", "budget", "estimate", "may", "will", and similar expressions identify forward-looking information and statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Xebra as of the dates of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. Such factors include, but are not limited to, the inability of Xebra to retain the authorizations granted by COFEPRIS, failure to receive required regulatory approvals for securities offerings, the inability to generate sufficient revenues or to raise sufficient funds to carry out its business plan; changes in government legislation, taxation, controls, regulations and political or economic developments in various countries; risks associated with agriculture and cultivation activities generally, including inclement weather, access to supply of seeds, poor crop yields, and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the risk of obtaining necessary licenses and permits; inability to identify, negotiate and complete potential acquisitions, dispositions or joint ventures for any reason; the ability to retain key employees; dependence on third parties for services and supplies; non-performance by contractual counter-parties; general economic conditions; the continued growth in global demand for cannabis products and the continued increase in jurisdictions legalizing cannabis; and the timely receipt of regulatory approvals for license applications on terms satisfactory to Xebra. In addition, there is no assurance Xebra will: be a low-cost producer or exporter; obtain a dominant market position in any jurisdiction; have products that will be unique. The foregoing list is not exhaustive and Xebra undertakes no obligation to update or revise any of the foregoing except as required by law. Many of these uncertainties and contingencies could affect Xebra's actual performance and cause its actual performance to differ materially from what has been expressed or implied in any forward-looking statements made by, or on behalf of, Xebra. Readers are cautioned that forward-looking statements are not guarantees of future performance and readers should not place undue reliance on such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those set out in such statements.

根據適用的證券法,本新聞稿中包含的某些信息構成前瞻性陳述。任何不是歷史事實陳述的陳述都可能被視爲前瞻性陳述,其中包括但不限於有關Xebra Brands Ltd的陳述。”對其成功執行商業計劃或商業模式的能力、獲得與債務清算相關的必要批准的能力、以可接受的條件建立和執行合夥企業或合資機會的能力、在其運營或將來可能運營的社區提供經濟、環境、社會或任何類型的福利的能力、成爲一個國家的先行者或獲得政府留住能力方面的期望一般執照、許可證或授權,或特別是在墨西哥、加拿大或其他地方,包括墨西哥衛生監管局(COFEPRIS)的大麻授權;其滿足COFEPRIS授予的授權條件的能力;在任何司法管轄區成功申請、獲得和保留商標和其他知識產權的能力;具有成本競爭力的能力;其在墨西哥、加拿大或其他地方商業化、種植、種植或加工大麻或大麻的能力以及相關的計劃和時機;其製造、商業化或銷售其 CBD 的能力墨西哥、加拿大或其他地方的產品、健康產品或其他產品,及其相關計劃和主張,包括市場興趣和供應情況;其生產具有治療效果或益處的健康產品的能力;未來增長計劃和業務方向;增加產品數量、現有設施產能、第三方種植者和承包商供應的計劃;大麻行業的總體預期增長;管理層的總體預期、信念和假設,包括製造成本,墨西哥或任何司法管轄區的生產活動和市場潛力;Xebra 預計未來發生的事件或發展;總體經濟狀況;以及截至2023年11月30日的公司管理與分析報告中所述的其他風險因素。除歷史事實陳述外,所有陳述均爲前瞻性信息和陳述。“目標”、“相信”、“期望”、“預期”、“考慮”、“目標”、“打算”、“繼續”、“計劃”、“預算”、“估計”、“可能”、“將” 等詞語以及類似的表述指向前瞻性信息和陳述。前瞻性陳述必然基於許多估計和假設,儘管截至此類陳述發佈之日,Xebra認爲這些估計和假設是合理的,但本質上會受到重大的業務、經濟和競爭不確定性和突發事件的影響。已知和未知因素可能導致實際業績與前瞻性陳述中的預測存在重大差異。這些因素包括但不限於:Xebra無法保留COFEPRIS授予的授權,證券發行未獲得監管部門所需的批准,無法創造足夠的收入或籌集足夠的資金來執行其業務計劃;各國的政府立法、稅收、控制、監管以及政治或經濟發展的變化;與農業和種植活動相關的總體風險,包括惡劣天氣、種子供應渠道,收成不佳產量和變質;遵守各國進出口法律;大麻價格和運輸成本的重大波動;獲得必要執照和許可證的風險;出於任何原因無法識別、談判和完成潛在的收購、處置或合資企業;留住關鍵員工的能力;依賴第三方提供服務和供應;合同對手不履行義務;總體經濟狀況;全球對大麻產品的需求持續增長和持續增長大麻合法化的司法管轄區有所增加;按照 Xebra 滿意的條款申請許可證的及時獲得監管部門的批准。此外,無法保證 Xebra 將:成爲低成本生產商或出口商;在任何司法管轄區獲得市場主導地位;擁有獨一無二的產品。上述清單並非詳盡無遺,除非法律要求,否則Xebra沒有義務更新或修改上述任何內容。這些不確定性和突發事件中有許多可能會影響Xebra的實際業績,並導致其實際表現與Xebra發表或代表Xebra所作的任何前瞻性陳述中所表達或暗示的內容存在重大差異。提醒讀者,前瞻性陳述並不能保證未來的表現,讀者不應過分依賴此類前瞻性陳述。無法保證此類陳述會被證明是準確的,實際結果和未來事件可能與此類聲明中列出的結果和未來事件有重大差異。

SOURCE: Xebra Brands Ltd.

來源:Xebra Brands Ltd.


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論